ArticleCommunications biology2025
Design of minibinder proteins as universal antagonists against canine and human TNFα.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we resolve the complex structure of canine TNFα (cTNFα) trimer bound to nanobody molecules at a resolution of 3.1 Å using cryo-electron microscopy. Structural comparison between cTNFα and human TNFα (hTNFα) reveals that the non-conserved residue Phe83 in cTNFα induces a conformational change in a nearby loop, which significantly reduces the binding affinity of cTNFα to nanobody TNF30. By analyzing the simulated complex structures of cTNFα with its receptors and resolved structures of hTNFα in complex with its receptors, we identify a conserved hydrophobic region involved in ligand-receptor interaction on both TNFαs. Five hydrophobic residues within this region are determined as target hotspots to allow de novo computational design of universal minibinders against both canine and human TNFα. Purified top-ranked designs exhibit sub-nanomolar to nanomolar affinity toward cTNFα as well as hTNFα, and show anti-TNFα activities to both TNFαs in cell-based assays that are comparable or superior to the anti-hTNFα activity of TNF30. This work provides a practical approach to generate universal TNFα antagonists as promising lead molecules for the development of potent cross-species biologics applicable in both humans and canines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.